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Abstract: TOBI® is a recently marketed preservative and sulphate free tobramycin formulation approved by FDA for 
maintenance therapy for patient with cystic fibrosis. The performance of selected recent nebuliser delivery systems has 
been assessed using the developed method to determine the optimum combinations to deliver approved tobramycin 
inhaled solution (TOBI)®. A simple, sensitive and specific high performance liquid chromatographic method has been 
developed and used to quantitative determination of the aminoglycoside tobramycin following pre-column derivatisation 
with phenylisocyanate (PIC). The reaction time was 10 min at 80º C and the resulting derivative was stable for five days 
at room temperature. The quantitative performance of the assay was further improved by using another aminoglycoside 
(neomycin) as internal standard. The stable resulting PIC-tobramycin derivative was separated using a HPLC 5µm 
Columbus C18 column (150x4.60 mm i.d, Phenomenex). The mobile phase was consisted of acetonitrile-glacial acetic 
acid-water (450:5:545, v/v/v) and ultraviolet detection at (240 nm). The proposed method showed good validation data. 
The standard curve was linear (n=5) at seven different concentrations, ranging from 20 to 140µg/ml and the correlation 
coefficient (R2) of the regression line was 0.9995. The limit of detection (LOD) and limit of quantitation (LOQ) were 
0.86µg/ml and 2.62µg/ml, respectively. The relative standard deviation (RSD %) was less than 0.6% for intra-day assay 
(n=5) and 2.5% for inter-day assay (n=5). A number of nebuliser performance comparison studies have been 
demonstrated for aerosolise TOBI® to choice the optimum combination produces high repirable inhaled mass of 
tobramycin. The objective of this study was to evaluate the performance of recent nebuliser delivery systems to nebulise 
approved tobramycin inhaled solution (TOBI)®. 
Keywords: Tobramycin, TOBI®, PIC derivatisation, HPLC, In vitro performance assessment, Nebuliser delivery 
systems. 
1. INTRODUCTION 
Aminoglycosides are a group of bactericidal drugs 
sharing chemical, antimicrobial, pharmacological, and 
toxic characteristics. 
Tobramycin is a broad spectrum aminoglycoside 
antibiotic first isolated in 1957 by investigators of Eli 
Lilly Research Laboratories. Seven antibiotic factors 
were isolated from Streptomyces Tenebrarius [1], and 
factor 6 was subsequently designated as tobramycin 
[2]. Tobramycin exhibits a broad spectrum against 
aerobic gram-negative bacteria especially 
Pseudomonas and indole positive Proteus [3] that 
makes it the antibiotic of choice in the treatment of 
pulmonary infections. 
Like the other aminoglycosides, tobramycin has 
narrow therapeutic range with potential nephrotoxicity 
and ototoxicity. Therefore, careful monitoring of the 
serum concentration of tobramycin is required to  
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achieve the optimal therapeutic level and to minimise 
toxicity. Tobramycin is a highly polar base that exhibits 
poor oral bioavailability, low protein binding (10%  
of absorbed drug), and excreted unchanged. 
Furthermore, it has a polycationic nature and therefore, 
it cross membranes very poorly, and does not cross the 
blood brain barrier, the CNS, nor penetrate ocular 
tissues. Therefore, it is administered by injection for 
systemic infections or topically (direct to the site of 
infection) for topical infections. The systemic availability 
of tobramycin that reflects the mass of inhaled drug 
deposited in the lungs can be calculated from the 
urinary excretion.  
TOBI® is specifically formulated for administration 
by inhalation. When inhaled, tobramycin is 
concentrated in the airways. The bioavailability of 
TOBI® may vary because of individual differences in 
nebuliser performance and airway pathology [4]. 
Following administration of TOBI®, tobramycin remains 
concentrated primarily in the airways. 
The most important characteristic for nebuliser 
performance assessment is the respirable mass output 
and the aerosol droplets size that are produced by 
Recent Nebuliser Delivery Systems for Nebulisation Journal of Applied Biopharmaceutics and Pharmacokinetics, 2015, Vol. 3, No. 2      35 
nebuliser device. The nebulisation time, simplicity of 
use, cost, and cleaning and sterilization requirements 
are also important characteristic for nebuliser 
performance assessment.  
By using breathing simulator (Pari Respiratory 
Equipment, Inc) and eight stages Marple 298 Cascade 
Impactors (Copley Scientific Limited, UK). In this study, 
in vitro performance assessment of recent nebuliser 
delivery systems for nebulisation of approved 
aerosolised tobramycin (TOBI)®. 
This study include a simple and sensitive HPLC 
method following pre-column derivatisation with 
phenylisocyanate (PIC) for the determination of 
tobramycin in pharmaceutical formulations has been 
developed. Aminoglycosides and most amines have 
very low absorbance in the UV-region, because these 
drugs do not have a significant UV absorbance 
chromophore, and fluorescence [5]. Moreover, these 
compounds difficult to retain on conventional HPLC 
columns because of their highly polar polycationic 
nature. Therefore, derivatisation with a suitable 
absorbance enhancing or fluorescence-producing 
agent is necessary to increase the detectability of these 
compounds by producing a highly detectable product 
easily for detection. Recently, a validated method for 
the determination of tobramycin by capillary electro-
phoresis after derivatisation with OPA/mercapto-
propionic acid (MPA) has been described [6].  
A number of HPLC pre-column derivatisation 
methods have been demonstrated with 2,4,6-
trinitrobenzenesulfonic acid (TNBS) [7,18], 1-fluro-2,4-
dinitrobenzene (FDNB) [4-7,26], O-phthaladehyde 
(OPA) [9-12] and 1-naphthyl isothiocyanate (NITC)[13]. 
The major drawback and limitation use of TNBS and 
FDNB reagents is due to their high toxicity and the 
main disadvantage of NITC reagent is length of time. 
Post-column derivatization methods have been 
demonstrated with o-phthaladehyde (OPA) [14-16]. 
The major disadvantage of the OPA reagent is the poor 
stability of the derivative.  
Recently, two new methods have been reported 
with detection modes are not readily available in every 
laboratory; ion-pair liquid chromatography with pulsed 
electrochemical detection (LC-PED) [17] and liquid 
chromatography-tandem mass spectrometry (LC-MS-
MS) [18] have been developed to determination of 
tobramycin without derivatisation with good 
repeatability. 
The main advantages of the proposed method are 
its simplicity, sensitivity, accuracy and that it gives a 
high stable PIC-tobramycin derivative in a short 
analysis time.  
2. EXPERIMENTAL 
2.1. Materials and Chemicals  
Tobramycin (98% purity) and neomycin sulphate 
(internal standard) were purchased from (Sigma-
Aldrich, Louis, USA). phenylisocyanate (PIC) that used 
as derivatising reagent was obtained from (Fluka 
chemie Gmbh, Switzerland),Glacial acetic acid was 
supplied by BDH (Pool, UK). All solvents used; 
acetonitrile, and methanol were HPLC grade and 
purchased from Fisher Scientific UK Limited 
(Loughborough, UK). All solutions were prepared with 
ultra-pure milli-Q water further purified for HPLC by 
using a (Milli-Q water Millipore purification system, 
USA). TOBI® (300mg/5 ml, Chiron Corporation, 
Emeryville, USA). The Pari LC Plus® attached to Pari 
BoyN® compressor (Pari Respiratory Equipment, Inc). 
Sidestream® attached to Porta-Neb® compressor 
(Profiles, UK). Omron NE-U22® high and low frequency 
(Omron, Japan). Aeroneb Go® (Aerogen, Inc, USA). 
Breathing simulator (Pari Respiratory Equipment, Inc). 
Eight stages Marple 298 Cascade Impactors (Copley 
Scientific Limited, UK). Vacuum controller model 
Erweka TPK (Copley Scientific Limited, UK). Mass flow 
meter model PR400 (MKS Instruments, Andover, MA, 
USA). 
3. METHODS 
3.1. HPLC Method Development 
3.1.1. Chromatographic Conditions 
The HPLC system consisted of Hewlett-Packard 
GmbH (HP) 1050 pump and autosampler connected to 
an on-line membrane degasser (Thermo Separation 
Product, California, USA). Hewlett-Packard (HP) 1050 
series variable wavelength UV detector was set at 
wavelength (240 nm), linked to Prime multichannel 
data station software (HPLC Technology, Ltd, Herts., 
UK).  
The chromatographic separation was carried out on 
a HPLC 5µm Columbus C18 column (150x4.60 mm i.d, 
Phenomenex, Macclesfield, UK) protected by a 
Phenomenex Security Guard cartridge column (C18, 
4x3 mm i.d). The mobile phase consisted of 
acetonitrile-glacial acetic acid-water (430:5:565, v/v/v). 
The mobile phase was filtered and degassed through a 
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nylon membrane filter 0.45µm pores (Gelman 
Sciences, Germany) under vacuum. 100µl of the 
derivatised sample were injected into the HPLC system 
and separated at ambient temperature using a constant 
flow rate of 1ml/min. 
3.1.2. Derivatisation Procedures 
In a 4-ml screw-capped glass vial, 1ml of 
tobramycin aqueous solution was mixed with 1ml of 
acetnitrile and derivatised with 300µl PIC (1%). 
Methanol (HPLC-grade) 300µl was added to the 
reaction mixture to react with the excess amount of PIC 
reagent, then the mixture was vortex mixed for 40 sec, 
and heated in water bath at 80º C for 15 minutes. After 
cooling, 50µl was injected into the HPLC system. 
3.1.3. Principle of Reaction 
Phenylisocyanate (PIC) reacts with both primary 
and secondary amine in alkaline medium and as well 
as reacts with hydroxy groups. The reaction is 
complete within 10 min, and the resulting derivative can 
be detected by UV absorbance at wavelength 254nm. 
As shown in Figure 1, PIC derivatising reagent reacts 
with the amino group in tobramycin, and other 
aminoglycosides, to form PIC-tobramycin derivative 
which is highly detectable compound. 
3.1.4. Optimisation of PIC Derivatisation Method  
The derivatisation of tobramycin with PIC 
derivatising reagent was optimised for reaction time 
and UV-detection wavelengths. The effect of reaction 
time was examined by allowing the derivatisation to 
proceed for various times ranging from 2 to 60 min in a 
water bath at 80º C. The reaction was completed within 
2 min, but the optimal was at 15 min, as shown in 
Figure 2. 
 
Figure 2: Effect of reaction time on PIC-Tobramycin 
derivative yield.  
The UV-detection was examined by detecting the 
repeated injections of standard tobramycin solution 
after PIC derivatisation at different wavelengths ranging 
from 230-270nm. The optimum detection of PIC-
tobramycin- derivative was detected at wavelength 
240nm, as shown in Figure 3. 
 
Figure 3: The Optimum UV-wavelengths for PIC-tobramycin 
derivative detection.  
 
Figure 1: Reaction of PIC with tobramycin. 
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3.1.5. PIC Derivatisation Method Validation 
3.1.5.1. Linearity 
The linearity of the HPLC pre-column PIC 
derivatisation method was examined by analysis of 
tobramycin standard solution at seven different 
concentrations, ranging from 20 to 140µg/ml. As shown 
in Figure 4, the standard calibration curve for 
tobramycin aqueous solution was linear, and described 
by the following equation:  
y = 0.0374x - 0.071 (n=5) 
The correlation coefficient in regression line of 
seven- point calibration was 0.9995. 
 
Figure 4: Calibration curve of tobramycin aqueous solution 
after PIC derivatisation. 
3.1.5.2. Sensitivity 
The LOD and LOQ of the HPLC pre-column PIC 
derivatisation method in tobramycin aqueous solution 
were calculated from the mean of the intercept of five 
calibration curves. The LOD and LOQ were 0.86 and 
2.62µg/ml, respectively. 
3.1.5.3. Precision 
Reproducibility of the assay in tobramycin aqueous 
solution was assessed: 
• Intra-day by five consecutive analyses of five 
different concentrations. 
• Inter-day also by five consecutive analyses of the 
same solutions on five days. 
The results of Intra-day and Inter-day precision are 
reported in Table 1. 
The reproducibility of the retention time of PIC-
tobramycin derivative was examined during the 
validation procedure of the analysis method after 
approximately 50 consecutive injections. The RSD % of 
the retention time was calculated to be 0.45, 0.389 % 
(n=50) for tobramycin and neomycin, respectively. 
Table 1: Intra-Day and Inter-Day Precision of 
Tobramycin Aqueous Solutions after PIC 
Derivatisation  
Tobramycin  
Concentration 
(µg/ml) 
Intra-day Inter-day 
STDEV RSD% STDEV RSD% 
20 0.00198 0.411664 0.008673 1.783705 
40 0.00416 0.604288 0.006004 0.871035 
60 0.002869 0.308969 0.007827 0.848462 
80 0.002401 0.213593 0.008297 0.737566 
100 0.002615 0.19289 0.035418 2.56713 
 
3.1.5.4. Specificity, Stability and Robustness 
The specificity of the assay was examined by 
testing samples to ensure that there were no 
interferences from components of the mobile phase, 
degradation products, other aminoglycosides and 
amino compounds, and common medications. No 
interferences were observed with tobramycin peak as 
shown in Figure 5.  
The stability of PIC-tobramycin derivative was 
examined by repeated injection of the same sample at 
different times over a period of 5 days, when stored at 
room temperature in a clear vial, and by comparing 
with freshly prepared standard.  
The stability of tobramycin solutions was also 
evaluated at room temperature for 24 hrs. and at 2°C in 
a refrigerator for 1, 3 and 6 months, then compared to 
freshly prepared solutions after PIC derivatisation. No 
significant differences were observed. The robustness 
of the assay was evaluated by determining the 
retention times of tobramycin using different lots of the 
same analytical column, and two different batches of 
mobile phase solvents. 
3.1.6. Application of the Developed HPLC Method 
3.1.6.1. Determination Amount of Tobramycin in 
Commercial Dosage Forms 
Many commercial dosage forms of tobramycin have 
been tested for determination amount of tobramycin by 
the developed HPLC method. The percentage of 
tobramycin free base in tobramycin sulphate was 
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detected theoretically and by the proposed HPLC 
method that is 65.6% so tobramycin sulphate 40mg/ml 
equivalent to 26,24mg/ml tobramycin free base.  
The tested dosage forms include TOBI® (300mg/5 
ml, Chiron Corporation, Emeryville, USA), Tobramycin 
injection B.P 80mg/2ml as Tobramycin sulphate (Cox 
pharmaceuticals.London.UK), and Tobramycin injection 
B.P 80mg/2ml as Tobramycin sulphate (David Bull 
Laboratories, Mulgrave, Victoria, Australia). The 
analysis assay was further improved by inject standard 
sample (as a control) inter three consecutive injections 
for quality control. The analysis data have been shown 
in Table 2. 
3.2. In vitro Measurements 
3.2.1. Study Design 
In this study, different nebuliser delivery systems 
have been used to assess their performance to deliver 
approved tobramycin inhaled solution 300mg/5ml 
(TOBI®; Chiron Corporation, Emeryville, USA): two 
different designs of jet nebulisers and two types of new 
nebulisers based on vibrating mesh technology. The 
two jet nebulisers were breath-enhanced Pari LC Plus® 
jet nebuliser attached to a PariBoyN® compressor (Pari 
GmbH, Starnberg, Germany), and the constant output 
Sidestream® jet nebuliser (Medic-Aid Ltd, West 
Sussex, UK) attached to a Porta-Neb® compressor 
(Profiles, UK). The performance of the Pari LC Plus® 
  
Figure 5: Chromatograms obtained for (A) a blank (water), (B) tobramycin with neomycin (internal standard) after derivatisation 
with PIC. 
Table 2: Determination of Amount of Tobramycin in Commercial Dosage Forms, using PIC Derivatisation Method 
Tobramycin pharmaceutical  
dosage forms 
Actual amount of Tobramycin  
(mg/ml) 
Found amount of Tobramycin (mg/ml) 
(Mean ±SD) (n=6) 
TOBI®  
(300mg/5 ml, Chiron Corporation, Emeryville, USA) 60 60 ± 0.057 
Tobramycin injection B.P 
(Cox Pharmaceuticals) 
26.24 
(as Tobramycin free base) 
26.20 ± 0.43 
Tobramycin injection B.P 
(David Bull Laboratories) 
26.24 
(as Tobramycin free base) 
26 ± 0.12 
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and Sidestream® was also assessed at different gas 
flow rates: 8L/min, using Medix® AC 2000 Hi Flow 
compressor (Medix, Ltd., UK), 10 and 12 L/min, using 
compressed air cylinder. The two types of new 
nebulisers were Omron® NE-U22 (Omron, Japan) 
ultrasonic vibrating mesh nebuliser with different 
frequencies (low, moderate, and high), and Aeroneb® 
Go (Aerogen, Inc., USA) electronic micropump 
nebuliser. The nebuliser fill volumes were 5ml and 
2.5ml of tobramycin inhaled solution 300mg/5ml 
(TOBI)® for jet and new nebuliser, respectively. The 
cascade impactor (Marple 298 series) was used to 
determine aerosol particle size distribution. The amount 
of tobramycin extracted from cascade filters was 
determined by HPLC.  
The particle size distribution measurements were 
calculated as the mean of six determinations. Breathing 
simulator modelling (Pari Respiratory Equipment, Inc., 
Germany) was used to determine total inhaled dose, 
aerosol output rate and percentage of inhaled mass, 
residual dose volume, and deposited dose. The 
methodology applied for the determination of the 
aerosol particle size distribution and output was 
adapted from the current European standard, EN 
13544-1:2001E “Respiratory therapy equipment – Part 
1: Nebulising systems and their components (approved 
by the European Committee for Standardisation CEN in 
June 2001 and published in August 2001). The 
European Standard is also a British Standard, BS EN 
13544-1:2001 British Standard, October 2001). 
The aerosol particle size distribution and aerosol 
output were determined at ambient conditions 
(temperature 23±2ºC, relative humidity 45% r.h to 75% 
r.h, and pressure from 86 kPa to 106 kPa). 
3.2.2. Data Analysis 
The aerosol particle size distribution measurements 
were calculated as the mean of six determinations. The 
cumulative mass of nebulized solution retained in the 
successive stages of the cascade impactor was 
calculated and plotted on a log-probability scale (as 
percentage of total mass recovered in the impactor) 
against the effective cut-off diameter. According to 
Clark and Borgstrom [19], the experimental mass 
median aerodynamic diameter (MMAD) of the particles 
was defined from this graph as the interpolation of the 
regression line at 50%, by using the Origin 6.1 software 
program.  
The fine particle fraction (FPF), defined as the 
fraction of the mass-weighted size distribution 
contained in particles smaller than a specified 
aerodynamic diameter, typically 5µm, is a descriptive 
statistic that was directly obtained from the cumulative 
mass fraction undersize (European Pharmacopoeia, 
1997).  
The geometric standard deviation (GSD) was 
calculated as recommended in the draft standard by 
the equation:  
 
GSD =
D84.13%
D15.87%
 
The span or volume median diameter (VMD), which 
is a measure of the width of the volume distribution 
relative to the median diameter, was calculated by the 
following equation:  
 
Span =
D90% !D10%
D50%
 
Span is an index of aerosol polydispersity [20]. The 
aerosol output measurements, which include inhaled 
dose in the first minute, aerosol output rate, respirable 
inhaled mass, respirable inhaled percentage, emitted 
dose, nebulisation time, and residual volume, were 
recorded as the mean of ten determinations. The 
inhalation rate was represented by amount of 
tobramycin in the first minute. The combination of 
particle size distribution and output results determined 
the optimum combinations to deliver approved 
tobramycin inhaled solution (TOBI)®. The statistical 
analysis was carried out using the SPSS (version 20) 
software program. The mean ratio (95% confidence 
interval) for all tested nebulisers was calculated. The 
Pari LC Plus® combined with the PariBoy® compressor 
was reference nebuliser. All tested nebulisers were 
compared to the reference by using a one-way ANOVA 
test A mean difference (99.9% confidence interval) was 
calculated also, and the probability value of p<0.001 
was considered to be significant. 
4. RESULTS AND DISCUSSIONS 
Nebuliser aerosol delivery is largely dependent on 
the nebuliser design and the physicochemical 
properties of drug solution. In this chapter, the effect of 
nebuliser design on improving tobramycin aerosol 
delivery has been studied by using different nebuliser 
delivery systems. The effect of changes in 
physicochemical properties of drug solution will be 
discussed in the next chapter. Different nebuliser 
delivery systems have been assessed to determine the 
optimum combination to deliver TOBI® solution and to 
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overcome the medication high cost problem by 
determining the best nebuliser system, characterised 
by high aerosol delivery and less drug wastage.  
Two different designs of jet nebulisers and new 
nebulisers based on vibrating mesh technology have 
been used. The constant output Sidestream® and 
breath-enhanced Pari LC Plus® jet nebulisers were 
used in combination with different compressors at 
different flow rates. The gas flow rate is the major 
determinant of the aerosol droplet size and the aerosol 
output of jet nebulisers. Thus, the influence of gas flow 
rate on tobramycin aerosol droplets size and output 
has been examined. The Sidestream® was combined 
with PotaNeb® compressor (flow rate 6.8 L/min), and 
Pari LC Plus® combined with PariBoyN® compressor 
(flow rate 7 L/min). Both the Sidestream® and Pari LC 
Plus® nebulisers were also combined with Medix® AC 
2000 Hi Flow compressor (flow rate 8 L/min) and 
compressed air cylinder, at flow rate 10 and 12 L/min. 
The analysis of particle size distribution measurements 
showed that the MMAD values decreased as air jet 
flow rate increased from 6.8-12 L/min, while the %FPF 
and VMD values were proportional to air jet flow rate. 
The mean (SD) of the smallest MMAD values in tested 
jet nebulisers was 1.22 (0.04), 1.33 (0.02) µm for 
Sidestream® and Pari LC Plus®, respectively, in 
combination with compressed air at flow rate 12L/min. 
The mean (SD) highest %FPF in tested jet 
nebulisers was 78 (1.11), 70 (1.13) % for Sidestream® 
and Pari LC Plus®, respectively, also in combination 
with compressed air at flow rate 12L/min. The 
difference in the results between both jet nebuliser 
systems was due to the difference in the internal 
design of the nebuliser. When comparing different 
frequencies (low, moderate and high) of NE-U22 
Omron® ultrasonic vibrating mesh nebuliser, the 
smallest droplet size was produced by moderate 
frequency. However, all tested nebulisers were 
produced droplets within the respirable size (2-5µm), 
as shown in Figure 6, but the smallest particle size was 
observed for NE-U22-E Omron® moderate frequency 
by mean (SD) 1.18 (0.03).  
The percentage of droplets less than 5µm was used 
to define the respirable (peripheral) percentage. The 
mean (SD) of highest droplets percentage (<5µm) was 
82.21 (1.72) % also for NE-U22-E Omron® moderate 
frequency, while the least droplets percentage value 
was 57.3 (2.58) % for Pari LC Plus® combined with 
PariBoyN® compressor. In general, the heterodispersity 
of aerosol produced from jet nebulisers was greater 
than the vibrating mesh nebulisers.  
All nebulised aerosol droplets were polydispersed 
with span values ranging between 2.93-5.37µm for jet 
nebulisers and 1.76-2.21µm for vibrating mesh 
nebulisers. The particle size distribution measurements 
are summarised in Table 3. The aerosol output was 
also affected by gas flow rate in jet nebulisers, the high 
flow rate leading to rapid evaporation of solvent and 
rapid decrease in the temperature of the fluid within the 
nebuliser, approximately 10 -15 º C [21, 23]. This may 
result in changes in the physiochemical properties of 
nebuliser fluids and precipitation of drug in the 
nebuliser [23]. The analysis data of aerosol output 
showed that the Medix® AC 2000 Hi Flow compressor 
(flow rate 8 L/min) was the optimum combination with 
both Sidestream® and Pari LC Plus® jet nebulisers 
which produced highest aerosol output when compared 
at different gas flow rates.  
0
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Figure 6: Mean (SD) MMAD obtained by different nebuliser systems during nebulisation of TOBI® solution.  
Key: P12 =Pari LC Plus® /air cylinder at flow rate 10 and 12 OL, OM and OH = low, moderate and high frequency of NE-U22 
Omron®, and AG= Aeroneb® Go. 
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All new nebulisers, NE-U22 Omron® (low, moderate, 
and high frequency) and Aeroneb Go®, showed a high 
percentage of respirable inhaled mass with fill volume 
less than jet nebulisers. The mean (SD) of highest 
percentage of respirable inhaled mass was 43 (1.15) % 
for the NE-U22-E Omron® (moderate frequency) 
nebuliser. The drug wastage was increased with jet 
nebulisers due to evaporation of solvent during jet 
nebulisation leading to a gradual increase in the 
concentration of drug solution left behind. For 
economic reasons, the mean (SD) of highest drug 
wastage percentage was 61.95 (1.78) % for the 
Sidestream® jet nebuliser combined with PotaNeb® 
compressor, while the mean (SD) least drug wastage 
percentage was 1.28 (0.27) % for the NE-U22-E 
Omron® (moderate frequency) nebuliser. In general, 
the drug wastage in vibrating mesh nebulisers was less 
than in jet nebulisers. The aerosol output 
characteristics are summarised in Table 4. All tested 
nebulisers were compared to Pari LC Plus®, which is 
recommended by the manufacturer of TOBI®, 
combined with PariBoyN® compressor, by using a one-
way ANOVA test.  
The statistic data showed that the MMAD values 
were significantly decreased (p< 0.001) by increasing 
the driven gas flow rate in both Pari LC Plus® and 
Sidestream® jet nebulisers. The fine particle dose and 
span values were significantly increased (p< 0.001) by 
increasing the gas flow rate in both jet nebulisers. 
When comparing the vibrating mesh nebulisers to the 
Pari LC Plus®/ PariBoyN® combination, the droplet size 
was significantly decreased (p< 0.001), while %FPF 
was significantly increased (p< 0.001) in NE-U22 
Omron® (moderate and high frequency) nebulisers. In 
vibrating mesh nebulisers, the percentage of respirable 
inhaled mass was significantly increased (p< 0.001), 
while the percentage of residual volume was 
significantly decreased (p< 0.001). Comparisons of 
tested nebulisers to Pari LC Plus® combined with 
PariBoyN® compressor are summarised in Tables 5 
and 6. When the results data of the particle size 
distribution and output measurements are combined, it 
Table 3:  Summary of Means (n=6) Aerosol Particle Size Distribution Measurements during Nebulisation of TOBI® 
Solution by Selected Nebuliser Delivery Systems 
Nebuliser Device 
MMAD µm GSD µm Fine Particles  <5 µm (mg) % FPF VMDµm 
Mean 
(SD) 95% CI 
Mean 
(SD) 95% CI 
Mean 
(SD) 95% CI 
Mean  
(SD) 95% CI 
Mean 
(SD) 
95% 
CI 
Sidestream®/  
Porta-Neb 1.96± 0.2 
1.72 – 
2.19 2.2 ± 0.05 
2.17 – 
2.27 1.5 ± 0.16 
1.30 –
1.64 60.6±4.05 
56.4 – 
64.9 2.9±0.3 
2.61 – 
3.24 
Sidestream®/  
Medix AC 2000 1.5±0.03 
1.47 – 
1.57 2.7 ±0.07 
2.59 – 
2.82 3.29±0.16 
3.0 – 
3.55 64.6±1.04 
62.9 – 
66.2 4.1±0.12 
3.94 – 
4.31 
Sidestream®/ 
Air 10L/min 1.38±0.05 
1.29 – 
1.45 2.88±0.04 
2.82 – 
2.94 4.18±0.26 
3.76 – 
4.59 69±2.12 
65.6 – 
72.2 4.16±0.23 
3.79 – 
4.52 
Sidestream®/ 
Air 12L/min 1.22±0.04 
1.17 – 
1.26 2.42±0.13 
2.28 – 
2.55 5.03±0.17 
4.85 – 
5.20 78.13± 1.1 
76.9 – 
79.3 3.41±0.17 
2.70 – 
3.79 
Pari LC Plus®/ 
PariBoy 1.99±0.17 
1.82 – 
2.17 2.67±0.14 
2.53 – 
2.81 2.2±0.23 
1.95 – 
2.43 57.3±2.58 
54.6 – 
60.0 3.48±0.23 
3.23 – 
3.71 
Pari LC Plus®/ 
Medix AC 2000 1.59±0.02 
1.56 – 
1.61 2.72±0.15 
2.56 – 
2.87 6.5±0.55 
5.92 – 
7.07 64.4±1.32 
63.0 – 
65.8 5.33±0.3 
4.99 – 
5.67 
Pari LC Plus®/Air 
10L/min 1.45±0.06 
1.42 – 
1.57 2.82±0.25 
2.50 – 
3.12 5.5±0.72 
4.60 – 
6.39 65.4±2.9 
61.8 – 
69.0 4.35±0.34 
3.92 – 
4.76 
Pari LC Plus®/ 
Air 12L/min 1.33±0.02 
1.31 – 
1.35 2.96 ±0.06 
2.90 – 
3.02 8.68±0.81 
7.82 – 
9.53 70.04±1.13 
68.8 – 
71.2 5.37±0.20 
5.19– 
5.53 
NE-U22 Omron® 
/ LF 2.12±0.2 
1.89 – 
2.34 1.76 ±0.06 
1.69 – 
1.83 1.20 ± 0.1 
1.09 – 
1.30 60.36±5.38 
54.7 – 
66.0 1.74±0.17 
1.56 – 
1.91 
NE-U22-E Omron® 
/ MF 1.18±0.03 
1.14 – 
1.21 1.99 ±0.08 
1.90 – 
2.08 3.44 ±0.26 
3.16 – 
3.71 82.21±1.72 
80.4 – 
84.0 2.60±0.18 
2.39 – 
2.78 
NE-U22 Omron® 
/ HF 2.63± 0.2 
2.42 – 
2.84 2.21±0.04 
2.16 – 
2.24 3.47 ±0.33 
3.13 – 
3.81 48.81±2.70 
45.9 – 
51.6 2.44±0.1 
2.34 – 
2.53 
Aeroneb Go® 2.02±0.08 1.93 – 2.10 2.11±0.07 
2.03 –
2.18 2.81±0.25 
2.54 – 
3.07 59.9 ± 1.4 
58.4 – 
61.4 2.62±0.08 
2.53 – 
2.70 
95% CI=Confidence Intervals. MMAD=Mass Median Aerodynamic Diameter, GSD= Geometric Standard Deviation, % FPF =Fine particle Fraction Percentage, 
VMD=Volume Median Diameter 
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can concluded that the moderate frequency NE-U22-E 
Omron® and Aeroneb Go® are preferred to nebulise 
TOBI® solution. The NE-U22-E Omron® moderate 
frequency showed the smallest aerosol droplets size, 
highest respirable droplets percentage, highest 
respirable inhaled mass, the least drug wastage, and 
reasonable nebulisation time, while Aeroneb Go® 
showed the shortest nebulisation time. 
Table 4: Summary of Means (n=10) Aerosol Output Measurements during Nebulisation of TOBI® Solution by Selected 
Nebuliser Delivery Systems 
Nebuliser Device 
Fill 
Volume 
(ml) 
Nebulisation 
Time (min) 
Inhalation Rate 
(mg/min) 
Respirable inhaled 
Mass (mg) 
% Respirable inhaled 
Mass 
% Residual of Dose 
Volume 
Mean 
(SD) 
95% 
CI 
Mean 
(SD) 
95% 
CI 
Mean 
(SD) 95% CI 
Mean 
(SD) 95% CI Mean (SD) 
95% 
CI 
Sidestream®/  
Porta-Neb 5 15±0.2 
14.8-
15.1 3.5 ± 0.2 
3.4 - 
3.7 32.3 ±2.1 
30.8- 
33.7 10.7 ±0.7 
10.2 -
11.2 61.9 ± 1.8 
60.6- 
63.2 
Sidestream®/  
Medix AC 2000 5 13.3±0.5 
12.6-
13.9 6.6 ± 0.1 
6.4 - 
6.8 56.8 ±1.2 
55.3- 
58.3 18.9 ±0.4 
18.4- 
19.4 36.2 ±0.7 
35.3- 
37.2 
Sidestream®/ 
Air 10L/min 5 10±0.14 
9.8 -
10.2 8.2 ± 0.2 
7.9 - 
8.5 56.9 ±1.5 55- 58.8 18.9 ±0.5 
18.3- 
19.6 37.2 ±0.9 
36.1- 
38.4 
Sidestream®/ 
Air 12L/min 5 8.5±0.16 
8.3 - 
8.6 5.6 ± 0.3 
5.4 - 
5.8 37.3±1.82 
36 - 
38.6 12.4 ± 0.6 
12 -  
12.8 56.3 ±2.1 
54.8- 
57.9 
Pari LC Plus®/ 
PariBoy 5
 13±0.33 12.9 -13.2 6.6 ± 0.3 
6.4 - 
6.9 49.5 ± 2.5 
47.6- 
51.3 16.5 ±0.8 
15.9- 
17.1 41.2 ±2.1 
39.7- 
42.7 
Pari LC Plus®/ 
Medix AC 2000 5 11.3±0.3 
10.9 -
11.6 7.2±0.6 
6.5 -
7.9 52.5 ± 4.2 
47.2- 
57.8 17.5 ±1.4 
15.7- 
19.2 38.3 ± 7.8 
28.5- 
48.1 
Pari LC Plus® / 
Air 10L/min 5 10.7±0.1 
10.5 -
10.8 7.7±0.42 
7.2 - 
8.2 54.2 ± 2.9 
50.6- 
57.8 18.1±0.97 
16.8- 
19.3 42.8 ±3.9 
37.9- 
47.7 
Pari LC Plus® 
/Air 12L/min 5 9±0.21 
8.7 - 
9.26 8.17±0.2 
7.8 - 
8.4 51.5 ±1.5 
49.6- 
53.3 17.2 ±0.5 
16.5- 
17.7 39.8 ±1.5 
37.9- 
41.6 
NE-U22 Omron®  
/ LF 2.5 20±0.36 
19.7 -
20.2 3.3±0.1 
3.2 - 
3.4 39.8 ± 1.6 
38.6- 
40.9 26.5 ±1 
25.7- 
27.3 4.7 ±0.38 
4.42 – 
4.9 
NE-U22-E 
Omron® / MF 2.5 15.4±0.2 
15.3 -
15.6 5.11±0.1 
5.0 - 
5.2 64.9 ±1.7 
63.6- 
66.1 43.2 ±1.1 
42.4- 
44.1 1.3 ±0.3 
1.1 - 
1.47 
NE-U22 Omron®  
/ HF 2.5 8.2±0.17 
8.1 - 
8.3 7.81±0.2 
7.6 - 
7.9 38.8 ±1 
38.1- 
39.5 25.9±0.67 
25.4- 
26.4 5.1 ± 0.3 
4.9 - 
5.2 
Aeroneb Go® 2.5 7 ± 0.09 6.97.06 10.04±1.7 
9.7 -
10.3 42.1 ±1.9 
40.7- 
48.6 28.1 ± 1.3 
27.1- 
28.9 25.9 ± 1.9 
24.5- 
27.3 
95% CI= Confidence Intervals.  
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Figure 7: Mean (SD) respirable inhaled mass percentage of tobramycin produced by selected nebuliser systems during 
nebulisation of a TOBI® solution.  
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5. CONCLUSIONS 
A simple, accurate and sensitive HPLC method for 
the determination of tobramycin followed by 
phenylisocyanate (PIC) pre-column derivatisation has 
been developed.  
The good validation results of the proposed method 
show the suitability to use it in the clinical and research 
laboratories for the measurement of tobramycin and 
other aminoglycosides in biological fluids or 
pharmaceutical formulations. The main advantages of 
the proposed method are the high sensitivity and 
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Figure 8: Mean (SD) residual volume percentage of tobramycin after nebulisation of a TOBI® solution by selected nebuliser 
systems.  
Table 5: Mean Difference (99.9% CI) of Particle Size Measurements Obtained by Selected High Performance Nebuliser 
Systems Compared to Recommended Pari LC Plus® Jet Nebuliser Combined with PariBoyN®, using One-Way 
ANOVA Test (Tukey HSD) 
 
MMAD µm GSD µm Fine Particles <5 µm (mg) % FPF VMD µm 
MD 
99.9% CI 
MD 
99.9% CI 
MD 
99.9% CI 
MD 
99.9% CI 
M D 
99.9% CI 
LB UB LB UB LB UB LB UB LB UB 
Sidestream®/  
Porta-Ne 0.038 -0.31 0.38 0.450* 0.148 0.750 0.724 -0.37 1.82 -3.350 -10.61 3.903 0.557 -0.15 1.27 
Sidestream®/ 
Medix AC 0.474* 0.086 0.86 -0.037* -0.373 0.298 -1.089 -2.313 0.134 -7.287 -15.39 0.821 -0.643 -1.44 0.15 
Sidestream®/ 
Air 10L/min 0.624* 0.24 1.012 -0.209 -0.545 0.127 -1.979* -3.203 -0.755 -11.685* -19.79 -3.576 -0.677* -1.47 0.12 
Sidestream®/ 
Air 12L/min 0.775* 0.429 1.122 -0.257 -0.043 0.558 -2.831* -3.925 -1.74 -20.810* -28.05 -13.55 0.070 -0.52 0.66 
Pari LCPlus®/ 
Medix AC 0.412* 0.065 0.76 -0.045 -0.346 0.255 -4.297* -5.392 -3.203 -7.093 -14.34 0.159 -1.846* -2.56 -1.13 
Pari LC Plus®/  
Air 10L/min 0.499* 0.136 0.86 -0.139 -0.455 0.175 -3.301* -4.44 -2.153 -8.103* -15.71 -0.496 -0.862* -1.61 -0.12 
Pari LC Plus®/  
Air 12L/min 0.665* 0.318 1.012 -0.285 -0.585 0.015 -6.480* -7.574 -5.385 -12.720* -19.97 -5.47 -1.879* -2.59 -1.17 
NE-U22 
Omron®/ LF -0.121 -0.47 0.23 0.915* 0.614 1.215 0.996 -0.099 2.089 -3.036 -10.23 4.216 1.746* 1.03 2.46 
NE-U22-E 
Omron® / MF 0.820* 0.472 1.16 0.681* 0.380 0.982 -1.244* -2.339 -0.149 -24.890* -32.14 -17.63 0.899* 0.19 1.61 
NE-U22 
Omron®/ HF -0.637* -0.98 -0.290 0.467* 0.166 0.767 -1.275* -2.370 -0.181 8.511* 1.258 15.76 1.045* 0.33 1.76 
Aeroneb Go® -0.021 -0.37 0.325 0.568* 0.267 0.870 -0.613 -1.707 0.482 -2.610 -9.861 4.643 0.865* 0.15 1.58 
99.9% CI=Confidence Intervals. 
LB=Lower Bound, UB=Upper Bound. 
MD=Mean Difference. 
*Mean difference significant at 0.001 level (p<0.001). 
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stability of PIC-tobramycin derivative and short run time 
of analysis.  
The performance of recent selected nebulisers 
evaluated to nebulise tobramycin inhaled solution, 
using the HPLC developed method. The NE-U22 
Omron® moderate frequency and Aeroneb Go® and 
were the best that are greater inhaled mass, less 
residual volume and short treatment time. 
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